ClinicalTrials.gg
CompletedNCT04124926Updated Jul 29, 2022Results posted

Efficacy and Safety of Vonoprazan Compared to Lansoprazole in Participants With Erosive Esophagitis

A Phase 3 interventional study of Vonoprazan and Lansoprazole in Erosive Esophagitis, sponsored by Phathom Pharmaceuticals, Inc.. Completed at 157 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-07-29.

Sponsored by Phathom Pharmaceuticals, Inc. · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,027
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies testing vonoprazan in Esophagitis — 1 open to participants now, 1 under way, none of them phase 3. vonoprazan · Esophagitis.

Enrollment
Largest of 10
1,027 · median 357
Started
2019
the only one that year
Phase 3
7 of 10
none open now
Registered
8th of 10
by date
Lead sponsor
1 of 10
Phathom Pharmaceuticals, Inc.

Among the 10 studies testing vonoprazan in Esophagitis, this one has the largest enrollment, is the only one that started in 2019, is one of 7 in phase 3, and was the 8th registered.

Esophagitis

123 studies on the registry are indexed under Esophagitis; 15 are open to participants now.

Browse Esophagitis studies →

Open to participants now

1 of the 10 studies testing vonoprazan in Esophagitis is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About vonoprazan

vonoprazan: first FDA approval 2022 (VOQUEZNA TRIPLE PAK). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 10 Esophagitis studies recruiting now, 6 (60%) set no upper age limit and 4 (40%) stop at 75 or younger; 2 take children under 18; 1 takes healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies testing vonoprazan in Esophagitis, or all of them as a file.
02

Study summary

To evaluate the efficacy and safety of vonoprazan compared to lansoprazole in participants with erosive esophagitis.

03

Conditions studied

  • Erosive Esophagitis

Browse trials for

Keywords

  • Erosive Esophagitis
  • Vonoprazan
  • Lansoprazole
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. The participant is ≥18 years of age at the time of signing.
  2. In the opinion of the investigator or subinvestigators, the participant is capable of understanding and complying with protocol requirements.
  3. The participant signs and dates a written, informed consent form and any required privacy authorization prior to the initiation of any study procedures. The participant is informed of the full nature and purpose of the study, including possible risks and side-effects. The participant has the ability to cooperate with the investigator. Ample time and opportunity should be given to read and understand verbal and/or written instructions.
  4. The participant is found to have endoscopically confirmed EE of LA Classification Grades A to D during the Screening Period (Visit 1) as assessed by a central adjudicator. The target number of participants with LA classification Grade C or D will be approximately 30% of the total number of participants (300 total). Enrollment of EE participants with Grade A or B will end when the number of participants with Grade A or B EE is approximately 700 or 70% of the total planned number of participants. Given the invasive nature of an endoscopy, any endoscopic confirmation performed in a routine clinical setting before signing the informed consent will be acceptable to use for the purpose of fulfilling the screening requirement if all of the following apply: (1) appropriate endoscopy pictures were taken; (2) appropriate gastric samples were taken; (3) the endoscopy pictures can be sent to the central adjudicator via the adjudication systems; and (4) all screening procedures (including the completion of adjudication) AND randomization can be completed within a 7-day period after the date of the endoscopy.
  5. A female participant of who is or may be sexually active with a nonsterilized male partner agrees to routinely use adequate from the signing of informed consent until 4 weeks after the last dose of study drug.

Exclusion criteria

Exclusion Criteria:

  1. The participant's endoscopic examination for entering this study fails to confirm EE within 7 days (no later than 10 days on rare occasion with sponsor approval) prior to randomization.
  2. The participant is determined to be positive for Helicobacter pylori (HP) or has had an HP infection within 45 days of randomization.
  3. The participant has endoscopic Barrett's esophagus (>1 cm of columnar-lined esophagus) and/or definite dysplastic changes in the esophagus.
  4. The participant has any other condition affecting the esophagus, including eosinophilic esophagitis; esophageal varices; viral or fungal infection; esophageal stricture; a history of radiation therapy, radiofrequency ablation, endoscopic mucosal resection, or cryotherapy to the esophagus; or any history of caustic or physiochemical trauma (including sclerotherapy or esophageal variceal band ligation). However, participants diagnosed with Schatzki's ring (mucosal tissue ring around lower esophageal sphincter) are eligible to participate.
  5. The participant has scleroderma (systemic sclerosis).
  6. The participant has a history of surgery or endoscopic treatment affecting gastroesophageal reflux, including fundoplication and dilation for esophageal stricture (except Schatzki's ring) or a history of gastric or duodenal surgery (except endoscopic removal of benign polyps).
  7. The participant has an active gastric or duodenal ulcer at the start of the Screening Period. Additionally, participants with gastric or duodenal erosions are permitted to participate.
  8. The participant has received any compound (including those in post marketing studies) within 30 days prior to the start of the Screening Period. A participant who has been screen failed from another clinical study and who has not been dosed may be considered for enrollment in this study.
  9. The participant is a study site employee, an immediate family member, or is in a dependent relationship with a study site employee who is involved in the conduct of this study (eg, spouse, parent, child, sibling) or who may have consented under duress.
  10. The participant has cutaneous lupus erythematosus or systemic lupus erythematosus.
  11. The participant has had upper or lower gastrointestinal bleeding within 4 weeks prior to randomization.
  12. The participant has Zollinger-Ellison syndrome or other gastric acid hypersecretory conditions.
  13. The participant has a history of or allergies to vonoprazan (including the formulation : D-mannitol, microcrystalline cellulose, hydroxypropyl cellulose, fumaric acid, croscarmellose sodium, magnesium stearate, hypromellose, macrogol 8000, titanium oxide, or red or yellow ferric oxide), PPIs, or any excipients used in the 13C-urea breath test: mannitol, citric acid, or aspartame. Skin testing may be performed according to local standard practice to confirm hypersensitivity.
  14. The participant has a history of alcohol abuse, illegal drug use, or drug addiction within the 12 months prior to screening, or regularly consumes >21 units of alcohol (1 unit = 12 oz/300 mL beer, 1.5 oz/25 mL hard liquor/spirits, or 5 oz/100 mL wine) per week based on self-report. Participants must have a negative urine drug screen at screening.
  15. The participant is taking any excluded medications or treatments.
  16. If female, the participant is pregnant, lactating, or intending to become pregnant before, during, or within 4 weeks after participating in this study; or intending to donate ova during such time period.
  17. The participant has a history or clinical manifestations of significant central nervous system, cardiovascular, pulmonary, hepatic, renal, metabolic, other gastrointestinal, urological, endocrine, or hematological disease that, in the opinion of the investigator, would confound the study results or compromise participant safety.
  18. The participant requires hospitalization or has surgery scheduled during the course of the study or has undergone major surgical procedures within 30 days prior to the Screening Visit.
  19. The participant has a history of (including MALToma) or has been treated for malignancy within 5 years prior to the start of the Screening Period (Visit 1). (The participant may be included in the study if he/she has cured cutaneous basal cell carcinoma or cervical carcinoma in situ).
  20. The participant has acquired immunodeficiency syndrome or infection, or tests positive for the surface antigen, virus (HCV) antibody, or HCV RNA. However, participants who test positive for HCV antibody but negative for HCV RNA are permitted to participate.
  21. The participant has any of the following abnormal laboratory test values at the start of the Screening Period:

    1. Creatinine levels: >2 mg/dL (>177 μmol/L)
    2. or aspartate aminotransferase >2 × the (ULN) or total >2 × ULN.
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
1,027 participants (actual)

Study arms

  • Experimental
    Healing Phase: Vonoprazan 20 mg

    Participants will receive oral vonoprazan 20 mg once per day (QD) for a maximum of 8 weeks.

    Drug: Vonoprazan

  • Active comparator
    Healing Phase: Lansoprazole 30 mg

    Participants will receive oral lansoprazole 30 mg once per day (QD) for a maximum of 8 weeks.

    Drug: Lansoprazole

  • Experimental
    Maintenance Phase: Vonoprazan 10 mg

    Participants will receive oral vonoprazan 10 mg once per day (QD) for a maximum of 24 weeks.

    Drug: Vonoprazan

  • Experimental
    Maintenance Phase: Vonoprazan 20 mg

    Participants will receive oral vonoprazan 20 mg once per day (QD) for a maximum of 24 weeks.

    Drug: Vonoprazan

  • Active comparator
    Maintenance Phase: Lansoprazole 15 mg

    Participants will receive oral lansoprazole 15 mg once per day (QD) for a maximum of 24 weeks.

    Drug: Lansoprazole

Interventions

  • Over-encapsulated tablet administered orally with approximately 240 mL water, 30 minutes prior to the morning meal.

  • Over-encapsulated capsule administered orally with approximately 240 mL water, 30 minutes prior to the morning meal.

06

What researchers measure

Primary outcomes

  1. Healing Phase: Percentage of Participants Who Had Complete Healing of EE by Week 8

    A participant was considered to have complete healing of EE if healing was demonstrated during endoscopy.

    Time frame: Week 8

  2. Maintenance Phase: Percentage of Participants Who Maintained Complete Healing of EE at Week 24

    A participant was considered to have complete healing of EE if healing was demonstrated during endoscopy.

    Time frame: Week 24

Secondary outcomes

  1. Healing Phase: Percentage of 24-hour Heartburn-free Days

    A 24-hour heartburn-free day was defined as a day having no heartburn among all diary entries for that day. The percentage of 24-hour heartburn-free days was calculated using all days with at least 1 evening or morning diary entry during the treatment period of this phase.

    Time frame: Day 1 to Week 8

  2. Healing Phase: Percentage of Participants With Baseline LA Classification Grades C or D Who Had Complete Healing of EE at Week 2

    A participant was considered to have complete healing of EE if healing was demonstrated during endoscopy. LA Classification of Esophagitis Grading Scale: Grade C: One or more mucosal breaks that are continuous between the tops of 2 or more mucosal folds, which involves less than 75% of the circumference. Grade D: One or more mucosal breaks, which involves at least 75% of the circumference.

    Time frame: Week 2

  3. Healing Phase: Percentage of Participants With Onset of Sustained Resolution of Heartburn by Day 3

    Sustained resolution was defined as at least 7 consecutive days with no daytime or night time heartburn as assessed by the daily diary. A participant was considered to have sustained resolution of heartburn by Day 3 if the first day of the 7 consecutive days without symptoms was on Days 1, 2, or 3.

    Time frame: Day 1 to maximum of Day 10 (inclusive of 7 day heartburn assessment)

  4. Healing Phase: Percentage of Participants With Baseline LA Classification Grades C or D Who Had Complete Healing of EE by Week 8

    A participant was considered to have complete healing of EE if healing was demonstrated during endoscopy. LA Classification of Esophagitis Grading Scale: Grade C: One or more mucosal breaks that are continuous between the tops of 2 or more mucosal folds, which involves less than 75% of the circumference. Grade D: One or more mucosal breaks, which involves at least 75% of the circumference.

    Time frame: Week 8

  5. Healing Phase: Percentage of Participants Who Had Complete Healing of EE at Week 2

    A participant was considered to have complete healing of EE if healing was demonstrated during endoscopy.

    Time frame: Week 2

  6. Maintenance Phase: Percentage of Participants With Baseline LA Classification Grades C or D Who Maintained Complete Healing of EE at Week 24

    A participant was considered to have complete healing of EE if healing was demonstrated during endoscopy. LA Classification of Esophagitis Grading Scale: Grade C: One or more mucosal breaks that are continuous between the tops of 2 or more mucosal folds, which involves less than 75% of the circumference. Grade D: One or more mucosal breaks, which involves at least 75% of the circumference.

    Time frame: Week 24

  7. Maintenance Phase: Percentage of 24-hour Heartburn-free Days

    A 24-hour heartburn-free day was defined as a day having no heartburn among all diary entries for that day. The percentage of 24-hour heartburn-free days was calculated using all days with at least 1 evening or morning diary entry during the treatment period of this phase.

    Time frame: Day 1 to Week 24

07

Results

Posted Jul 29, 2022

Participant flow

This study was performed at 111 sites in 6 countries (Bulgaria, Czechia, Hungary, Poland, the United Kingdom and the United States) between 28 October 2019 and 24 August 2021. Of the 4,167 participants screened for the study, 1,027 participants with erosive esophagitis (EE) were randomized in the Healing Phase.

Healing Phase
Participant flow — Healing Phase
MilestoneHealing Phase: Vonoprazan 20 mgHealing Phase: Lansoprazole 30 mgMaintenance Phase: Vonoprazan 10 mgMaintenance Phase: Vonoprazan 20 mgMaintenance Phase: Lansoprazole 15 mg
Started514513000
Treated with study drug514510000
Completed483481000
Not completed3132000
Withdrew: Pretreatment event, adverse event (ae), or serious ae (sae)37000
Withdrew: Protocol violation01000
Withdrew: Lost to follow-up54000
Withdrew: Voluntary withdrawal107000
Withdrew: Withdrawal of consent53000
Withdrew: Miscellaneous87000
Withdrew: Randomized but not treated03000
Maintenance Phase
Participant flow — Maintenance Phase
MilestoneHealing Phase: Vonoprazan 20 mgHealing Phase: Lansoprazole 30 mgMaintenance Phase: Vonoprazan 10 mgMaintenance Phase: Vonoprazan 20 mgMaintenance Phase: Lansoprazole 15 mg
Started00298298297
Treated with study drug00296296297
Completed00274269269
Not completed00242928
Withdrew: Pretreatment event, ae, or sae00354
Withdrew: Protocol violation00300
Withdrew: Lost to follow-up00789
Withdrew: Voluntary withdrawal00365
Withdrew: Pregnancy00010
Withdrew: Lack of efficacy00001
Withdrew: Withdrawal of consent00555
Withdrew: Miscellaneous00124
Withdrew: Randomized but not treated00220

Outcome measures

PrimaryHealing Phase: Percentage of Participants Who Had Complete Healing of EE by Week 8

A participant was considered to have complete healing of EE if healing was demonstrated during endoscopy.

Time frame:
Week 8
Reported as:
Number · percentage of participants
Healing Phase: Percentage of Participants Who Had Complete Healing of EE by Week 8
percentage of participantsHealing Phase: Vonoprazan 20 mgHealing Phase: Lansoprazole 30 mg
Healing Phase: Percentage of Participants Who Had Complete Healing of EE by Week 892.984.6
Statistical analysis
  • Healing Phase: Vonoprazan 20 mg vs Healing Phase: Lansoprazole 30 mg · Farrington and Manning test · p = <0.0001 (2-sided p-value.) · Difference in percentage: 8.3 · 95% CI 4.49 to 12.23The 2-sided 95% confidence interval (CI) of the difference in EE healing rates between vonoprazan 20 mg and lansoprazole 30 mg was calculated via the Miettinen and Nurminen method.
PrimaryMaintenance Phase: Percentage of Participants Who Maintained Complete Healing of EE at Week 24

A participant was considered to have complete healing of EE if healing was demonstrated during endoscopy.

Time frame:
Week 24
Reported as:
Number · percentage of participants
Maintenance Phase: Percentage of Participants Who Maintained Complete Healing of EE at Week 24
percentage of participantsMaintenance Phase: Vonoprazan 10 mgMaintenance Phase: Vonoprazan 20 mgMaintenance Phase: Lansoprazole 15 mg
Maintenance Phase: Percentage of Participants Who Maintained Complete Healing of EE at Week 2479.280.772.0
Statistical analysis
  • Maintenance Phase: Vonoprazan 20 mg vs Maintenance Phase: Lansoprazole 15 mg · Farrington and Manning test · p = <0.0001 (2-sided p-value.) · Difference in percentage: 8.7 · 95% CI 1.80 to 15.53The 2-sided 95% CI of the difference in EE maintenance rates between each vonoprazan group and lansoprazole group was calculated via the Miettinen and Nurminen method.
  • Maintenance Phase: Vonoprazan 10 mg vs Maintenance Phase: Lansoprazole 15 mg · Farrington and Manning test · p = <0.0001 (2-sided p-value.) · Difference in percentage: 7.2 · 95% CI 0.21 to 14.09The 2-sided 95% CI of the difference in EE maintenance rates between each vonoprazan group and lansoprazole group was calculated via the Miettinen and Nurminen method.
  • Maintenance Phase: Vonoprazan 20 mg vs Maintenance Phase: Lansoprazole 15 mg · Farrington and Manning test · p = 0.0136 (2-sided p-value.)
  • Maintenance Phase: Vonoprazan 10 mg vs Maintenance Phase: Lansoprazole 15 mg · Farrington and Manning test · p = 0.0436 (2-sided p-value.)
SecondaryHealing Phase: Percentage of 24-hour Heartburn-free Days

A 24-hour heartburn-free day was defined as a day having no heartburn among all diary entries for that day. The percentage of 24-hour heartburn-free days was calculated using all days with at least 1 evening or morning diary entry during the treatment period of this phase.

Time frame:
Day 1 to Week 8
Reported as:
Mean · percentage of days
Healing Phase: Percentage of 24-hour Heartburn-free Days
percentage of daysHealing Phase: Vonoprazan 20 mgHealing Phase: Lansoprazole 30 mg
Healing Phase: Percentage of 24-hour Heartburn-free Days66.8 ± 34.6064.1 ± 35.46
Statistical analysis
  • Healing Phase: Vonoprazan 20 mg vs Healing Phase: Lansoprazole 30 mg · Difference in mean percentage: 2.7 · 95% CI -1.60 to 7.03The 2-sided 95% CI of the difference in mean percentage of 24-hour heartburn-free days between vonoprazan 20 mg and lansoprazole 30 mg was calculated from Welch's t-test.
SecondaryHealing Phase: Percentage of Participants With Baseline LA Classification Grades C or D Who Had Complete Healing of EE at Week 2

A participant was considered to have complete healing of EE if healing was demonstrated during endoscopy. LA Classification of Esophagitis Grading Scale: Grade C: One or more mucosal breaks that are continuous between the tops of 2 or more mucosal folds, which involves less than 75% of the circumference. Grade D: One or more mucosal breaks, which involves at least 75% of the circumference.

Time frame:
Week 2
Reported as:
Number · percentage of participants
Healing Phase: Percentage of Participants With Baseline LA Classification Grades C or D Who Had Complete Healing of EE at Week 2
percentage of participantsHealing Phase: Vonoprazan 20 mgHealing Phase: Lansoprazole 30 mg
Healing Phase: Percentage of Participants With Baseline LA Classification Grades C or D Who Had Complete Healing of EE at Week 270.252.6
Statistical analysis
  • Healing Phase: Vonoprazan 20 mg vs Healing Phase: Lansoprazole 30 mg · Farrington and Manning test · p = 0.0008 (2-sided p-value.) · Difference in percentage: 17.6 · 95% CI 7.44 to 27.43The 2-sided 95% CI of the difference in EE healing rates between vonoprazan 20 mg and lansoprazole 30 mg was calculated via the Miettinen and Nurminen method.
SecondaryHealing Phase: Percentage of Participants With Onset of Sustained Resolution of Heartburn by Day 3

Sustained resolution was defined as at least 7 consecutive days with no daytime or night time heartburn as assessed by the daily diary. A participant was considered to have sustained resolution of heartburn by Day 3 if the first day of the 7 consecutive days without symptoms was on Days 1, 2, or 3.

Time frame:
Day 1 to maximum of Day 10 (inclusive of 7 day heartburn assessment)
Reported as:
Number · percentage of participants
Healing Phase: Percentage of Participants With Onset of Sustained Resolution of Heartburn by Day 3
percentage of participantsHealing Phase: Vonoprazan 20 mgHealing Phase: Lansoprazole 30 mg
Healing Phase: Percentage of Participants With Onset of Sustained Resolution of Heartburn by Day 334.432.2
Statistical analysis
  • Healing Phase: Vonoprazan 20 mg vs Healing Phase: Lansoprazole 30 mg · Farrington and Manning test · p = 0.4392 (2-sided p-value.) · Difference in percentage: 2.3 · 95% CI -3.50 to 8.04The 2-sided 95% CI of the difference in sustained resolution rates between vonoprazan 20 mg and lansoprazole 30 mg was calculated via the Miettinen and Nurminen method.
SecondaryHealing Phase: Percentage of Participants With Baseline LA Classification Grades C or D Who Had Complete Healing of EE by Week 8

A participant was considered to have complete healing of EE if healing was demonstrated during endoscopy. LA Classification of Esophagitis Grading Scale: Grade C: One or more mucosal breaks that are continuous between the tops of 2 or more mucosal folds, which involves less than 75% of the circumference. Grade D: One or more mucosal breaks, which involves at least 75% of the circumference.

Time frame:
Week 8
Reported as:
Number · percentage of participants
Healing Phase: Percentage of Participants With Baseline LA Classification Grades C or D Who Had Complete Healing of EE by Week 8
percentage of participantsHealing Phase: Vonoprazan 20 mgHealing Phase: Lansoprazole 30 mg
Healing Phase: Percentage of Participants With Baseline LA Classification Grades C or D Who Had Complete Healing of EE by Week 891.772.0
Statistical analysis
  • Healing Phase: Vonoprazan 20 mg vs Healing Phase: Lansoprazole 30 mg · Farrington and Manning test · p = <0.0001 (2-sided p-value.) · Difference in percentage: 19.6 · 95% CI 11.84 to 27.58The 2-sided 95% CI of the difference in EE healing rates between vonoprazan 20 mg and lansoprazole 30 mg was calculated via the Miettinen and Nurminen method.
SecondaryHealing Phase: Percentage of Participants Who Had Complete Healing of EE at Week 2

A participant was considered to have complete healing of EE if healing was demonstrated during endoscopy.

Time frame:
Week 2
Reported as:
Number · percentage of participants
Healing Phase: Percentage of Participants Who Had Complete Healing of EE at Week 2
percentage of participantsHealing Phase: Vonoprazan 20 mgHealing Phase: Lansoprazole 30 mg
Healing Phase: Percentage of Participants Who Had Complete Healing of EE at Week 274.368.2
Statistical analysis
  • Healing Phase: Vonoprazan 20 mg vs Healing Phase: Lansoprazole 30 mg · Farrington and Manning test · p = 0.0348 (2-sided p-value.) · Difference in percentage: 6.1 · 95% CI 0.53 to 11.60The 2-sided 95% CI of the difference in EE healing rates between vonoprazan 20 mg and lansoprazole 30 mg was calculated via the Miettinen and Nurminen method.
SecondaryMaintenance Phase: Percentage of Participants With Baseline LA Classification Grades C or D Who Maintained Complete Healing of EE at Week 24

A participant was considered to have complete healing of EE if healing was demonstrated during endoscopy. LA Classification of Esophagitis Grading Scale: Grade C: One or more mucosal breaks that are continuous between the tops of 2 or more mucosal folds, which involves less than 75% of the circumference. Grade D: One or more mucosal breaks, which involves at least 75% of the circumference.

Time frame:
Week 24
Reported as:
Number · percentage of participants
Maintenance Phase: Percentage of Participants With Baseline LA Classification Grades C or D Who Maintained Complete Healing of EE at Week 24
percentage of participantsMaintenance Phase: Vonoprazan 10 mgMaintenance Phase: Vonoprazan 20 mgMaintenance Phase: Lansoprazole 15 mg
Maintenance Phase: Percentage of Participants With Baseline LA Classification Grades C or D Who Maintained Complete Healing of EE at Week 2474.777.261.5
Statistical analysis
  • Maintenance Phase: Vonoprazan 20 mg vs Maintenance Phase: Lansoprazole 15 mg · Farrington and Manning test · p = 0.0196 (2-sided p-value.) · Difference in percentage: 15.7 · 95% CI 2.50 to 28.44The 2-sided 95% CI of the difference in maintenance rates between each vonoprazan group and lansoprazole 15 mg group was calculated via the Miettinen and Nurminen method.
  • Maintenance Phase: Vonoprazan 10 mg vs Maintenance Phase: Lansoprazole 15 mg · Farrington and Manning test · p = 0.0490 (2-sided p-value.) · Difference in percentage: 13.3 · 95% CI 0.02 to 26.14The 2-sided 95% CI of the difference in maintenance rates between each vonoprazan group and lansoprazole 15 mg group was calculated via the Miettinen and Nurminen method.
SecondaryMaintenance Phase: Percentage of 24-hour Heartburn-free Days

A 24-hour heartburn-free day was defined as a day having no heartburn among all diary entries for that day. The percentage of 24-hour heartburn-free days was calculated using all days with at least 1 evening or morning diary entry during the treatment period of this phase.

Time frame:
Day 1 to Week 24
Reported as:
Mean · percentage of days
Maintenance Phase: Percentage of 24-hour Heartburn-free Days
percentage of daysMaintenance Phase: Vonoprazan 10 mgMaintenance Phase: Vonoprazan 20 mgMaintenance Phase: Lansoprazole 15 mg
Maintenance Phase: Percentage of 24-hour Heartburn-free Days80.9 ± 28.5980.6 ± 29.9678.6 ± 27.49
Statistical analysis
  • Maintenance Phase: Vonoprazan 20 mg vs Maintenance Phase: Lansoprazole 15 mg · Difference in mean percentage: 2.0 · 95% CI -2.63 to 6.72The 2-sided 95% CI of the difference in mean percentage of 24-hour heartburn-free days between each vonoprazan group and the lansoprazole group was calculated from Welch's t-test.
  • Maintenance Phase: Vonoprazan 10 mg vs Maintenance Phase: Lansoprazole 15 mg · Difference in mean percentage: 2.3 · 95% CI -2.27 to 6.84The 2-sided 95% CI of the difference in mean percentage of 24-hour heartburn-free days between each vonoprazan group and the lansoprazole group was calculated from Welch's t-test.

Adverse events

Collected over Healing Phase: Day 1 to Week 8; Maintenance Phase: Day 1 to Week 28. Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Healing Phase: Vonoprazan 20 mg0/514 (0%)3/514 (0.6%)50/514 (9.7%)
Healing Phase: Lansoprazole 30 mg0/510 (0%)3/510 (0.6%)46/510 (9%)
Maintenance Phase: Vonoprazan 10 mg0/296 (0%)10/296 (3.4%)72/296 (24.3%)
Maintenance Phase: Vonoprazan 20 mg2/296 (0.7%)14/296 (4.7%)81/296 (27.4%)
Maintenance Phase: Lansoprazole 15 mg0/297 (0%)7/297 (2.4%)74/297 (24.9%)
Most frequent serious events
Showing 10 of 35
Most frequent serious events
EventHealing Phase: Vonoprazan 20 mgHealing Phase: Lansoprazole 30 mgMaintenance Phase: Vonoprazan 10 mgMaintenance Phase: Vonoprazan 20 mgMaintenance Phase: Lansoprazole 15 mg
COVID-19Infections and infestations1/5140/5101/2962/2960/297
COVID-19 pneumoniaInfections and infestations0/5140/5101/2962/2960/297
Oedema peripheralGeneral disorders1/5140/5100/2961/2960/297
DiverticulitisInfections and infestations0/5140/5101/2960/2960/297
Peritonsillar abscessInfections and infestations0/5140/5100/2961/2960/297
SinusitisInfections and infestations0/5140/5101/2960/2960/297
Large intestine polypGastrointestinal disorders0/5140/5101/2960/2960/297
MelaenaGastrointestinal disorders0/5140/5101/2960/2960/297
PancreatitisGastrointestinal disorders0/5140/5100/2961/2960/297
PancreatolithiasisGastrointestinal disorders0/5140/5100/2961/2960/297
Most frequent other events
Showing 10 of 13
Most frequent other events
EventHealing Phase: Vonoprazan 20 mgHealing Phase: Lansoprazole 30 mgMaintenance Phase: Vonoprazan 10 mgMaintenance Phase: Vonoprazan 20 mgMaintenance Phase: Lansoprazole 15 mg
COVID-19Infections and infestations8/5146/51012/29626/29618/297
DiarrhoeaGastrointestinal disorders11/51413/5103/2967/29613/297
DyspepsiaGastrointestinal disorders1/5143/51011/29612/2968/297
Gastrooesophageal reflux diseaseGastrointestinal disorders6/5142/5107/29611/2966/297
Abdominal painGastrointestinal disorders8/5142/5104/29610/2963/297
Chronic gastritisGastrointestinal disorders2/5141/5109/2964/2965/297
HypertensionVascular disorders3/5144/5109/2968/2966/297
Urinary tract infectionInfections and infestations6/5144/5108/2961/2965/297
Back painMusculoskeletal and connective tissue disorders2/5144/5106/2968/2964/297
HeadacheNervous system disorders6/5146/5103/2962/2968/297

Baseline characteristics

The Randomized Set included all participants randomly assigned to receive study drug regardless of whether or not they received a dose of study drug.

Age, Categorical
Age, Categorical(Participants)Healing Phase: Vonoprazan 20 mgHealing Phase: Lansoprazole 30 mgTotal
<=18 years000
Between 18 and 65 years421406827
>=65 years93107200
Sex: Female, Male
Sex: Female, Male(Participants)Healing Phase: Vonoprazan 20 mgHealing Phase: Lansoprazole 30 mgTotal
Female256289545
Male258224482
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Healing Phase: Vonoprazan 20 mgHealing Phase: Lansoprazole 30 mgTotal
Hispanic or Latino6259121
Not Hispanic or Latino450451901
Unknown or Not Reported235
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Healing Phase: Vonoprazan 20 mgHealing Phase: Lansoprazole 30 mgTotal
White474458932
Black or African-American234164
Asian7613
American Indian or Alaska Native213
Native Hawaiian or Other Pacific Islander112
Other5510
Unknown112
Not Reported101
Adjudicated Los Angeles (LA) Classification of Esophagitis Grading Scale
Adjudicated Los Angeles (LA) Classification of Esophagitis Grading Scale(Participants)Healing Phase: Vonoprazan 20 mgHealing Phase: Lansoprazole 30 mgTotal
Grade A or B337336673
Grade C or D177174351
Unknown or Not Reported033
08

Study locations

157 sites
  • Pinnacle Research Group
    Anniston, Alabama 36207, United States
  • North Alabama Research Center LLC
    Athens, Alabama 35611, United States
  • Synexus Clinical Research US, Inc.
    Birmingham, Alabama 35211, United States
  • Medical Affiliated Research Center Inc
    Huntsville, Alabama 35801, United States
  • Synexus Clinical Research US, Inc. - East Valley Family Physicians, PLC
    Chandler, Arizona 85224, United States
  • Synexus Clinical Research US, Inc. - Central Arizona Medical Associates, PC
    Mesa, Arizona 85206, United States
  • Synexus Clinical Research US, Inc. - Desert Clinical Research, LLC
    Mesa, Arizona 85213, United States
  • Elite Clinical Studies - Phoenix - BTC - PPDS
    Phoenix, Arizona 85018, United States
  • Hope Research Institute LLC
    Phoenix, Arizona 85018, United States
  • Del Sol Research Management - BTC - PPDS
    Tucson, Arizona 85712, United States
  • Preferred Research Partners - ClinEdge - PPDS
    Little Rock, Arkansas 72211, United States
  • Applied Research Center of Little Rock
    Little Rock, Arkansas 72212, United States
  • Arkansas Gastroenterology
    North Little Rock, Arkansas 72117, United States
  • Atria Clinical Research - BTC - PPDS
    North Little Rock, Arkansas 72117, United States
  • Anaheim Clinical Trials LLC
    Anaheim, California 92801, United States
  • GW Research, Inc. - ClinEdge - PPDS
    Chula Vista, California 91910, United States
  • eStudySite - Chula Vista - PPDS
    Chula Vista, California 91911, United States
  • Kindred Medical Institute for Clinical Trials, LLC
    Corona, California 92879, United States
  • HB Clinical Trials, Inc.
    Fountain Valley, California 92708-7510, United States
  • OM Research LLC
    Lancaster, California 93534, United States
  • Torrance Clinical Research Institute
    Lomita, California 90717, United States
  • LA County + USC Medical Center
    Los Angeles, California 90033, United States
  • Southern California Research Institute Medical Group, Inc.
    Los Angeles, California 90045, United States
  • Facey Medical Foundation
    Mission Hills, California 91345, United States
  • Palmtree Clinical Research
    Palm Springs, California 92262, United States
  • Precision Research Institute
    San Diego, California 92114, United States
  • Medical Associates Research Group, Inc.
    San Diego, California 92123, United States
  • Paragon Rx Clinical, Inc.
    Santa Ana, California 92703, United States
  • Synexus Clinical Research US, Inc. - Colorado Springs Family Practice
    Colorado Springs, Colorado 80909, United States
  • Western States Clinical Research, Inc.
    Wheat Ridge, Colorado 80033, United States
  • Gastroenterology Associates of Fairfield County
    Bridgeport, Connecticut 06606, United States
  • Connecticut Clinical Research Foundation
    Bristol, Connecticut 06010, United States
  • Riverside Clinical Research
    Edgewater, Florida 32132, United States
  • Research Centers of America - ERG
    Hollywood, Florida 33024, United States
  • Nature Coast Clinical Research
    Inverness, Florida 34452, United States
  • ENCORE Borland-Groover Clinical Research - ERN - PPDS
    Jacksonville, Florida 32256, United States
  • Columbus Clinical Services LLC
    Miami, Florida 33125, United States
  • Jesscan Medical Research
    Miami, Florida 33134, United States
  • Nuren Medical and Research Center
    Miami, Florida 33144, United States
  • Premier Research Associate, Inc.
    Miami, Florida 33165, United States
  • Gutierrez Medical Center
    Orlando, Florida 32807, United States
  • Advanced Gastroenterology Associates, LLC
    Palm Harbor, Florida 34684, United States
  • Innovation Medical Research Center
    Palmetto Bay, Florida 33157, United States
  • Synexus Clinical Research US, Inc. - St. Petersburg
    Pinellas Park, Florida 33781, United States
  • Precision Clinical Research, LLC
    Sunrise, Florida 33351, United States
  • Guardian Angel Research Center
    Tampa, Florida 33614, United States
  • Atlanta Gastroenterology Associates
    Atlanta, Georgia 30342, United States
  • Nexgen Research Center
    Atlanta, Georgia 30345, United States
  • Gastroenterology Associates of Central Georgia, LLC
    Macon, Georgia 31201, United States
  • In-Quest Medical Research, LLC
    Peachtree Corners, Georgia 30071, United States
  • Illinois Gastroenterology Group
    Gurnee, Illinois 60031, United States
  • Summit Digestive & Liver Disease Specialists State Street Clinic
    Oakbrook Terrace, Illinois 60181, United States
  • MediSphere Medical Research Center, LLC
    Evansville, Indiana 47714, United States
  • Gastroenterology Health Partners, PLLC
    New Albany, Indiana 47150, United States
  • Iowa Digestive Disease Center
    Clive, Iowa 50325, United States
  • Clinical Trials Management LLC
    Covington, Louisiana 70433, United States
  • CroNOLA, LLC.
    Houma, Louisiana 70360, United States
  • Clinical Trials Management LLC
    Metairie, Louisiana 70006, United States
  • Louisiana Research Center, LLC
    Shreveport, Louisiana 71105, United States
  • Meridian Clinical Research
    Rockville, Maryland 20854, United States
  • Clinical Associates Research
    Towson, Maryland 21286, United States
  • Oakland Medical Research Center
    Troy, Michigan 48085, United States
  • Gastroenterology Associates of Western Michigan, PLC
    Wyoming, Michigan 49519, United States
  • The Alliance for Multispecialty Research, LLC
    Kansas City, Missouri 64114, United States
  • Washington University School of Medicine
    Saint Louis, Missouri 63110, United States
  • Heartland Clinical Research, Inc
    Omaha, Nebraska 68134, United States
  • Synexus Clinical Research US, Inc. Site 1
    Henderson, Nevada 89052, United States
  • Synexus Clinical Research US, Inc. Site 2
    Henderson, Nevada 89052, United States
  • Sierra Clinical Research - ClinEdge - PPDS
    Las Vegas, Nevada 89106, United States
  • Site 2
    Las Vegas, Nevada 89119, United States
  • Las Vegas - Site 1
    Las Vegas, Nevada 89128, United States
  • Advanced Research Institute
    Reno, Nevada 89511, United States
  • Drug Trials America - ClinEdge
    Hartsdale, New York 10530, United States
  • Southtowns Gastroenterology, PLLC
    Orchard Park, New York 14127, United States
  • Carolinas Research Center
    Charlotte, North Carolina 28215, United States
  • Duke University Medical Center
    Durham, North Carolina 27710, United States
  • Medication Management LLC
    Greensboro, North Carolina 27408, United States
  • Carolina Research
    Greenville, North Carolina 27834, United States
  • Peters Medical Research, LLC - ClinEdge - PPDS
    High Point, North Carolina 27262, United States
  • Carolina's GI Research, LLC
    Raleigh, North Carolina 27607, United States
  • Dayton Gastroenterology, Inc
    Dayton, Ohio 45415, United States
  • Prestige Clinical Research
    Franklin, Ohio 45005, United States
  • Central Sooner Research
    Norman, Oklahoma 73071, United States
  • Synexus Clinical Research US, Inc.
    Anderson, South Carolina 29621, United States
  • Clinical Trials of South Carolina
    Charleston, South Carolina 29406, United States
  • Coastal Carolina Research Center
    Mount Pleasant, South Carolina 29464, United States
  • Rapid City Medical Center LLP
    Rapid City, South Dakota 57701, United States
  • Multi Specialty Clinical Research
    Johnson City, Tennessee 37601, United States
  • Clinical Research Associates Inc
    Nashville, Tennessee 37203, United States
  • Vanderbilt University Medical Center
    Nashville, Tennessee 37212, United States
  • Inquest Clinical Research
    Baytown, Texas 77521, United States
  • Synexus Clinical Research US, Inc. - Dallas
    Dallas, Texas 75234, United States
  • Texas Tech University Health Sciences Center El Paso
    El Paso, Texas 79905, United States
  • Precision Research Institute, LLC
    Houston, Texas 77036, United States
  • Biopharma Informatic, LLC
    Houston, Texas 77084, United States
  • Rio Grande Gastroenterology
    McAllen, Texas 78503, United States
  • Digestive System Healthcare
    Pasadena, Texas 77505, United States
  • Pearland Physicians
    Pearland, Texas 77581, United States
  • Synexus Clinical Research US, Inc.
    Plano, Texas 75093, United States
  • Quality Research Inc
    San Antonio, Texas 78209, United States

Showing the first 100 of 157 sites across 6 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Laine L, DeVault K, Katz P, Mitev S, Lowe J, Hunt B, Spechler S. Vonoprazan Versus Lansoprazole for Healing and Maintenance of Healing of Erosive Esophagitis: A Randomized Trial. Gastroenterology. 2023 Jan;164(1):61-71. doi: 10.1053/j.gastro.2022.09.041. Epub 2022 Oct 10. PubMed 36228734 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Undecided — Data from this study will be published; however, it is undecided if patient level data will be made available at this time.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2019 to primary completion in Jul 2021, 21 months.

Results were first posted in Jul 2022, 1 year after primary completion.

Of 18 phase 3 interventional studies under Esophagitis, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 34. This study's 21 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 10, 2019
First posted
Oct 14, 2019
StartActual
Oct 28, 2019
Primary completionActual
Jul 29, 2021
CompletionActual
Aug 24, 2021
Results first posted
Jul 29, 2022
Last update
Jul 29, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 29, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04124926
Lead sponsor
Phathom Pharmaceuticals, Inc.
Responsible party
Sponsor
First posted
Oct 14, 2019
Start date
Oct 28, 2019
Primary completion
Jul 29, 2021
Completion
Aug 24, 2021
Results posted
Jul 29, 2022
Last update
Jul 29, 2022

Study contacts

Medical Director
study director · Phathom Pharmaceuticals

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Vonoprazan

Start the discussion